Skip to main content
Contact Us
Subscribe
E-Edition
46°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AC Immune S.A.
(NQ:
ACIU
)
3.150
-0.030 (-0.94%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AC Immune S.A.
< Previous
1
2
Next >
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
November 14, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
November 13, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 05, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
September 17, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
August 28, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
July 31, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
July 25, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
July 16, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
May 28, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 13, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
March 14, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
February 22, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
January 22, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
January 03, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Pricing of Underwritten Offering of Common Shares
December 15, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
December 15, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
December 01, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
November 07, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 03, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
November 02, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
October 27, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
October 17, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
October 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
September 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 04, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
July 28, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune SA Appoints New Chief Medical Officer
July 26, 2023
From
AC Immune SA
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.